Dr. Peter Nigrovic’s research focuses on understanding mechanisms of inflammatory arthritis, using both human samples and mouse models. These studies have helped to illuminate the roles played by mast cells, neutrophils and platelets, among other cell types. In studies supported by ANRF, his group has identified a new pathway by which entry of neutrophils could potentially be targeted to treat inflammatory arthritis, and is pursuing the role of sugars (glycans) attached to antibodies that alter their ability to engage the immune system. He directs biorepositories of arthritis samples at two Harvard-affiliated hospitals, Boston Children’s Hospital and the Brigham and Women’s Hospital. Dr. Nigrovic earned his M.D. at Harvard Medical School in 1995 and his research was funded by grants from the ANRF to Dr. Nigrovic and affiliated researchers since 2009.
He serves on the editorial board of Arthritis & Rheumatology and on the Steering Committee of the US/Canadian pediatric research collaborative CARRA (the Childhood Arthritis and Rheumatology Research Alliance). He is an award-winning mentor for junior scientists and was founding co-chair of AMIGO, the American College of Rheumatology’s inter-institutional mentoring program in pediatric rheumatology. Dr. Nigrovic sees both adult and children with arthritis, with a particular interest in systemic juvenile idiopathic arthritis and on the lifelong care of arthritis in children.
Part One: Inflammatory Arthritis Therapy with Dr. Nivgrovic
Part Two: Inflammatory Arthritis Therapy with Dr. Nivgrovic